Roche’s Giredestrant ASCO Play Is a Signal to Every Endocrine Therapy Competitor
Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...
early breast cancer
Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...